Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs Queen RX

Coivas
Graded #194

Lower grade

vs+0.09999999999999432
Queen RX
Graded #192

Higher grade

The verdict

Queen RX takes it — 66.3/100 to 66.2/100, but only just.

Queen RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Queen RX offers compounded GLP-1 treatment (semaglutide, tirzepatide, liraglutide) at $299/quarter (~$100/mo). Coivas is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +7
70
77
Dose & formulationCoivas +7
64
57
Clinical oversightCoivas +15
84
69
Labs & monitoringCoivas +1
54
53
FulfillmentCoivas +3
78
75
Contract termsQueen RX +41
20
61
Coivas · left barQueen RX · right bar

The numbers

MetricCoivasQueen RX
WeighScore66.2/10066.3/100
GradeCC
Scorecard rank#194#192
Semaglutide$149/mo (quarterly plan, compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$229/mo (quarterly plan, compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Coivas

Graded #194 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
Queen RX

Graded #192 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard